Extensive serum biomarker analysis in patients with macrophage activation syndrome associated with systemic lupus erythematosus.
CXCL9
Macrophage activation syndrome
Soluble tumor necrosis factor receptor type II
Systemic lupus erythematosus
Journal
Clinical immunology (Orlando, Fla.)
ISSN: 1521-7035
Titre abrégé: Clin Immunol
Pays: United States
ID NLM: 100883537
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
18
06
2019
revised:
27
08
2019
accepted:
30
08
2019
pubmed:
3
9
2019
medline:
20
5
2020
entrez:
3
9
2019
Statut:
ppublish
Résumé
The present study employed an antibody array that simultaneously detects 174 cytokines to identify cytokines involved in the development of macrophage activation syndrome (MAS) associated with systemic lupus erythematosus (SLE) with a view to elucidating potential predictive markers. Eight SLE patients, including four with MAS, were analyzed. Levels of 31 cytokines were significantly elevated in the MAS phase compared with those in the active phase of SLE. Among these cytokines, the MAS/active phase ratios of CXCL9 and soluble tumor necrosis factor receptor II (sTNFR-II) were highest. Elevated serum CXCL9 and sTNFR-II levels during the MAS phase were confirmed by ELISA and were strongly correlated with other inflammatory markers, reflecting the disease activity of MAS associated with SLE. These results highlight the clinical significance of serum CXCL-9 and sTNFR-II levels, and indicate they may be useful biomarkers for the diagnosis of MAS associated with SLE.
Identifiants
pubmed: 31476438
pii: S1521-6616(19)30322-5
doi: 10.1016/j.clim.2019.108255
pii:
doi:
Substances chimiques
Biomarkers
0
CXCL9 protein, human
0
Chemokine CXCL9
0
Receptors, Tumor Necrosis Factor, Type II
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
108255Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.